These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 19642244

  • 21. Estimating renal function in patients on tenofovir disoproxil fumarate: suggestions for safer use.
    Winston J, Shepp DH.
    HIV Med; 2006 Oct; 7(7):484-5. PubMed ID: 16925736
    [No Abstract] [Full Text] [Related]

  • 22. Anti-HIV agents. Dueling nukes: AZT + 3TC vs. tenofovir + FTC.
    TreatmentUpdate; 2005 Oct; 17(5):5-7. PubMed ID: 17225279
    [No Abstract] [Full Text] [Related]

  • 23. Acute renal failure after initiation of tenofovir disoproxil fumarate.
    Hynes P, Urbina A, McMeeking A, Barisoni L, Rabenou R.
    Ren Fail; 2007 Oct; 29(8):1063-6. PubMed ID: 18067059
    [Abstract] [Full Text] [Related]

  • 24. Tenofovir-induced nephrotoxicity: myths and facts.
    Gupta A, Bugeja A, Kirpalani D.
    Saudi J Kidney Dis Transpl; 2012 Jan; 23(1):148-9. PubMed ID: 22237241
    [No Abstract] [Full Text] [Related]

  • 25. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
    Irizarry-Alvarado JM, Dwyer JP, Brumble LM, Alvarez S, Mendez JC.
    AIDS Read; 2009 Mar; 19(3):114-21. PubMed ID: 19334328
    [Abstract] [Full Text] [Related]

  • 26. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
    Côté HC, Magil AB, Harris M, Scarth BJ, Gadawski I, Wang N, Yu E, Yip B, Zalunardo N, Werb R, Hogg R, Harrigan PR, Montaner JS.
    Antivir Ther; 2006 Mar; 11(1):79-86. PubMed ID: 16518963
    [Abstract] [Full Text] [Related]

  • 27. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
    MMW Fortschr Med; 2002 Aug 22; 144(33-34):61. PubMed ID: 12380158
    [No Abstract] [Full Text] [Related]

  • 28. Anti-HIV agents. The puzzle of virologic failure with tenofovir.
    TreatmentUpdate; 2004 Aug 22; 16(3):4. PubMed ID: 17216834
    [No Abstract] [Full Text] [Related]

  • 29. Improvement in chronic renal impairment following the discontinuation of tenofovir in two HIV-infected patients.
    Gracey D, Post J, MacLeod C, McKenzie P.
    Nephrology (Carlton); 2011 May 22; 16(4):453-5. PubMed ID: 21518120
    [No Abstract] [Full Text] [Related]

  • 30. [Acute renal failure and proximal renal tubular dysfuntion in a patient with acquired immunodeficiency syndrome treated with tenofovir].
    de la Prada FJ, Prados AM, Tugores A, Uriol M, Saus C, Morey A.
    Nefrologia; 2006 May 22; 26(5):626-30. PubMed ID: 17117909
    [Abstract] [Full Text] [Related]

  • 31. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
    Gallant JE, Parish MA, Keruly JC, Moore RD.
    Clin Infect Dis; 2005 Apr 15; 40(8):1194-8. PubMed ID: 15791522
    [Abstract] [Full Text] [Related]

  • 32. 96-week CASTLE data show similar efficacy results.
    AIDS Patient Care STDS; 2008 Nov 15; 22(11):918. PubMed ID: 19043840
    [No Abstract] [Full Text] [Related]

  • 33. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy.
    Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW.
    HIV Med; 2005 Sep 15; 6(5):341-6. PubMed ID: 16156882
    [Abstract] [Full Text] [Related]

  • 34. Tenofovir: FDA hearing October 3, public comment deadlines September 26.
    James JS.
    AIDS Treat News; 2001 Aug 24; (370):3-4. PubMed ID: 11570163
    [No Abstract] [Full Text] [Related]

  • 35. Effect of tenofovir on renal glomerular and tubular function.
    Fux CA, Christen A, Zgraggen S, Mohaupt MG, Furrer H.
    AIDS; 2007 Jul 11; 21(11):1483-5. PubMed ID: 17589197
    [Abstract] [Full Text] [Related]

  • 36. Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure.
    Ter Heine R, Huitema AD, Jansen RS, Smits PH, van Gorp EC, Wagenaar JF, Beijnen JH, Mulder JW.
    Antivir Ther; 2009 Jul 11; 14(2):299-301. PubMed ID: 19430105
    [Abstract] [Full Text] [Related]

  • 37. Adverse events experienced by three children taking tenofovir and didanosine in combination.
    Hawkins S, Ball C.
    HIV Med; 2007 Sep 11; 8(6):411. PubMed ID: 17661851
    [No Abstract] [Full Text] [Related]

  • 38. Initial results reported on raltegravir once-daily dosing.
    AIDS Patient Care STDS; 2011 Feb 11; 25(2):123. PubMed ID: 21370546
    [No Abstract] [Full Text] [Related]

  • 39. Hypokalemia in HIV patients on tenofovir.
    Cirino CM, Kan VL.
    AIDS; 2006 Aug 01; 20(12):1671-3. PubMed ID: 16868451
    [Abstract] [Full Text] [Related]

  • 40. Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context.
    Szczech LA.
    J Infect Dis; 2008 Jan 01; 197(1):7-9. PubMed ID: 18171278
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.